Přihlásit se Zaregistrujte se zdarma

Hotovost/akcie společnosti Adma Biologics Inc

Jaká je hodnota metriky Hotovost/akcie společnosti Adma Biologics Inc?

Hodnota metriky Hotovost/akcie společnosti Adma Biologics Inc je 1.25

Jaká je definice metriky Hotovost/akcie?

Účetní hodnota akcie (Book/Share) se rovná majetku společnosti minus závazky společnosti dělené počtem vydaných akcií.

Cash per share, sometimes called the cash share ratio, is the total cash per share. Cash on hand is reported on the balance sheet. Cash per share is calculated by dividing cash on hand by the total number of shares. Cash per share is the percentage of a firm's share price that is immediately accessible for spending. Cash per share consists of cash and short-term investments. It is money that a firm has on hand and does not come from borrowing or financing activities.

When a firm has a high cash per share, significant percentage of its assets is in a very liquid form. This can indicate economic uncertainty and unwillingness to invest given the current economic climate. High levels of cash per share can indicate that a firm is performing well and is able to reinvest in itself but high cash per share does not always indicate overall financial strength.

Hotovost/akcie společností v sektoru Health Care sektor na NASDAQ ve srovnání se společností Adma Biologics Inc

Čemu se věnuje společnost Adma Biologics Inc?

adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.

Firmy s metrikou hotovost/akcie podobnou společnosti Adma Biologics Inc